Top Markets
#1 Cortex Cortex +32.77%
#2 龙虾 (Lobster) 龙虾 (Lobster) +26.17%
#3 Akedo Akedo +23.49%
#4 DexNet DexNet +23.19%
#5 Pons Pons +17.70%
#6 wojak wojak +15.91%
#7 OpenEden OpenEden +15.43%
#8 APEX APEX +13.92%
#9 Verus Coin Verus Coin +13.77%
#10 TDCCP TDCCP +11.86%
Coin of the day
Cortex Cortex
Setări
Limbă
ROMâNă
Monedă
USD
Temă
HBM Holdings Limited HBM Holdings Limited

HBM Holdings Limited

2142
Rang în acțiuni #7297
HBM Holdings Limited is a clinical-stage biopharmaceutical enterprise focused... HBM Holdings Limited is a clinical-stage biopharmaceutical enterprise focused on identifying and developing unique antibody-based treatments for a variety of immunological conditions and cancers. The company's pipeline includes several promising assets. In immunology, Batoclimab (HBM9161) is a human monoclonal antibody specifically designed to bind and inhibit the neonatal fragment crystallizable receptor, while Tanfanercept (HBM9036) is under development to address moderate to severe dry eye disease. For oncology, HBM Holdings is advancing various therapies, such as HBM7008, a bispecific antibody targeting tumor-associated antigens, and HBM4003, a human anti-CTLA-4 antibody. Additional cancer candidates in their portfolio include HBM9302 for breast and gastric cancers, HBM7020 for multiple myeloma, and a suite of treatments—HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022—geared towards solid tumors. Furthermore, HBM9022 is being developed to treat SARS-COV-2. Operating globally, HBM Holdings has a presence in Mainland China, the United States, Europe, and other international markets. The company also fosters strategic partnerships for antibody-drug conjugate (ADC) projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was founded in 2016 and is based in Shanghai, People's Republic of China.
Preț acțiune
$1.95
Capitalizare de piață
$1.64B
Schimbare (1 zi)
-6.69%
Schimbare (1 an)
19.42%
Țară
CN
Tranzacționează HBM Holdings Limited (2142)

Categorie

Healthcare
Venituri pentru HBM Holdings Limited (2142)
Venituri în Aug 2026 TTM: 0
Conform celor mai recente rapoarte financiare ale HBM Holdings Limited, venitul actual al companiei (TTM) este 0. În anul 2026, compania a avut un venit de 0 egal cu venitul din anul 2026, care a fost de 0. Venitul reprezintă suma totală generată de o companie din vânzarea de bunuri sau servicii. Spre deosebire de profit, cheltuielile nu sunt scăzute.
Istoricul veniturilor pentru HBM Holdings Limited din 2026 până în 2026
Venituri la sfârșitul fiecărui an
An Venituri Schimbă
Nu sunt suficiente date pentru perioada selectată.
Venituri pentru companii similare sau concurente
Companie Venituri Diferență de venituri Țara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH